Research Article
To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice
Table 2
Indication for laboratory assessment of DOAC level.
| | | Overall N = 119 | Apixaban n = 62 | Rivaroxaban n = 57 |
| | Urgent/emergent procedure | 38 (32) | 28 (45) | 10 (18) | | Acute kidney injury | 17 (14) | 10 (16) | 7 (12) | | Bleed event on DOAC | 11 (9) | 5 (8) | 6 (11) | | Recurrent VTE on DOAC | 10 (8) | 5 (8) | 5 (9) | | Thrombophilia | 9 (8) | 0 (0) | 9 (16) | | Other | 7 (6) | 2 (3) | 5 (9) | | History of recurrent VTE pre-DOAC | 6 (5) | 0 (0) | 6 (11) | | High body weight | 16 (13) | 10 (16) | 6 (11) | | Low body weight | 5 (4) | 2 (3) | 3 (5) |
|
|
